Advertisement
Screener

MAZE THERAPEUTICS, INC. (MAZE) Cash and Restricted Cash

2.8 / 5 stars · 68/120 Roast Me

MAZE THERAPEUTICS, INC. Cash and Restricted Cash

MAZE THERAPEUTICS, INC. (MAZE) had Cash and Restricted Cash of $203.73 million as of 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11

  • 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $203.73M.
  • 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $199.85M.
  • 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $190.34M.
  • 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $317.86M.
Period endCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
2026-06-30$203.73M
10-Q · filed 2026-08-11
2026-03-31$199.85M
10-Q · filed 2026-05-12
2025-12-31$190.34M
10-Q · filed 2026-08-11
2025-09-30$317.86M
10-Q · filed 2025-11-06
2025-06-30$265.63M
10-Q · filed 2026-08-11
2025-03-31$295.46M
10-Q · filed 2026-05-12
2024-12-31$197.90M
10-Q · filed 2026-08-11
2024-09-30$150.69M
10-Q · filed 2025-11-06
2024-06-30$176.15M
10-Q · filed 2025-08-12
2024-03-31$31.11M
10-Q · filed 2025-05-14
2023-12-31$30.25M
10-K · filed 2026-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
NOVAVAX INC (NVAX)United States$1.748B-6.26
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81